BRF (BRFS3) Q4 2025 earnings summary

Executive summary

• Achieved highest volume and revenue since the consolidation of BRF in 2022, driven by a diversified multi-protein platform and strong brands.

• Net revenue reached R$65,049 million in 2025, a 6.0% increase year-over-year, driven by a 4.5% rise in sales volume and a 1.4% higher average price, despite currency headwinds and sector challenges.

• Adjusted EBITDA was R$10,419 million, slightly down 0.8% from 2024, with a margin of 16.0% (vs. 17.1% in 2024), reflecting higher costs and inflationary pressures.

• Net income totaled R$3,288 million, a decrease of 10.9% compared to 2024, with a net margin of 5.1%.

• The year was marked by the first avian influenza case in Brazil, temporary export restrictions, and the completion of the Marfrig merger, making the company a wholly owned subsidiary.

Financial highlights

• Gross profit reached R$16,406 million, up 3.6% year-over-year, with a gross margin of 25.2% (down 0.6 p.p.).

• Operating income (EBIT) was R$6,646 million, down 2.8% from 2024.

• Net debt increased to R$9,393 million, up R$1,068 million from 2024.

• Cash and equivalents at year-end were R$14,448 million, up from R$11,165 million in 2024.

• Adjusted EBITDA margin declined by 1.1 p.p. to 16.0%.

Outlook and guidance

• Management expects continued growth in processed foods and international markets, with ongoing investments in production capacity and market expansion, especially in the Middle East and Asia.

• The company is monitoring the impact of the Middle East conflict but reports no material effects on operations or supply chain as of the report date.

• Commitment to disciplined capital structure and liquidity management.